Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
04:05pm, Tuesday, 07'th May 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences i
Exelixis (EXEL) International Revenue Performance Explored
01:11pm, Monday, 06'th May 2024
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
10:16am, Wednesday, 01'st May 2024
Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.
Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript
09:27pm, Tuesday, 30'th Apr 2024
Exelixis, Inc. (NASDAQ:EXEL ) Q1 2024 Earnings Conference Call April 30, 2024 5:00 PM ET Company Participants Varant Shirvanian - Director of Investor Relations Michael Morrissey - President and Chief
Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to Say
07:31pm, Tuesday, 30'th Apr 2024
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 30'th Apr 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives
The Top 3 Biotech Stocks to Buy in April 2024
07:00am, Saturday, 27'th Apr 2024
Biotech stocks are notorious for being some of the most volatile and unpredictable on the market. With clinical trials and FDA approvals creating potential leaps or falls in what seems like an instant
EXEL vs. REGN: Which Stock Is the Better Value Option?
12:45pm, Thursday, 25'th Apr 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks is more attractive to value inve
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
04:05pm, Tuesday, 16'th Apr 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:
EXEL or REGN: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 09'th Apr 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks presents investors with the better value o
2 More Potential Biotech Buyout Targets
01:07pm, Monday, 25'th Mar 2024
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
08:36am, Friday, 08'th Mar 2024
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
2 Biotech Stocks to Buy Hand Over Fist in March
08:15am, Friday, 08'th Mar 2024
Regeneron boasts a pair of growth drivers that should still have plenty of fuel left. Exelixis is close to expanding its lineup with a promising late-stage candidate.
Why Is Exelixis (EXEL) Up 10.9% Since Last Earnings Report?
12:36pm, Thursday, 07'th Mar 2024
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
04:45pm, Wednesday, 06'th Mar 2024
Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA) approval. T
